Details:
NBI-1117570 is an investigational, oral, muscarinic M1/M4 dual agonist. Muscarinic receptors are fundamental to activating signaling pathways in the brain.
Lead Product(s): NBI-1117570
Therapeutic Area: Neurology Product Name: NBI-1117570
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Lecanemab (BAN2401) is an investigational humanized monoclonal antibody for Alzheimer's disease selectively binds to neutralize and eliminate soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: BioArctic AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
The trial is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of a single ascending dose and multiple ascending doses of subcutaneous HTL0022562 in healthy adult subjects.
Lead Product(s): BHV3100
Therapeutic Area: Neurology Product Name: HTL0022562
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
Lilly will be responsible for future global development and regulatory activities for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies.
Lead Product(s): AK1780
Therapeutic Area: Neurology Product Name: AK1780
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $410.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement January 29, 2021
Details:
AbbVie has notified that it will be returning to Sosei Heptares all assets in development under the program including HTL0018318, all intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the partnership.
Lead Product(s): HTL0018318
Therapeutic Area: Neurology Product Name: HTL0018318
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Allergan Aesthetics
Deal Size: $3,290.0 million Upfront Cash: $125.0 million
Deal Type: Terminated January 05, 2021
Details:
Tempero Bio will obtain exclusive global rights to a portfolio of potent, orally available metabotropic glutamate receptor 5 NAM modulators, including HTL0014242, which were precision-designed by Sosei Heptares using its GPCR Structure-Based Drug Design (SBDD) platform.
Lead Product(s): HTL0014242
Therapeutic Area: Neurology Product Name: TMP-301
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Aditum Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 02, 2020